CVS settles with FTC, agrees to count TrumpRx drug purchases towards…

CVS Caremark settles with the FTC, agreeing to count TrumpRx purchases toward insurance deductibles, eliminate rebate-based pricing models, and cap insulin out-of-pocket costs at $25/month. The settlement mirrors earlier enforcement against Cigna and Express Scripts, and regulators estimate it will save billions on drug prices. If you're building any alternative to pharmacy benefit managers—discount networks, direct-to-consumer pharma, or employer drug-purchasing platforms—the FTC just handed you your pitch: rebate models are now toxic, and CVS has been forced to build what you're selling. Employers and insurers are watching this settlement; they now have permission to switch.